Unknown

Dataset Information

0

Trastuzumab emtansine: the first targeted chemotherapy for treatment of breast cancer.


ABSTRACT: Trastuzumab emtansine (T-DM1) is a novel antibody-drug conjugate, comprised of a potent cytotoxic drug connected via a stable linker to the anti-HER2 antibody, trastuzumab, thereby primarily targeting chemotherapy delivery to cells overexpressing the HER2 receptor. A Phase II randomized trial of T-DM1 in the front-line metastatic breast cancer setting revealed promising activity and improved safety compared with standard chemotherapy plus trastuzumab. Subsequently, a Phase III trial in patients with trastuzumab-pretreated metastatic breast cancer showed T-DM1 to be associated with prolonged progression-free and overall survival compared with lapatinib plus capecitabine. T-DM1 represents a major shift in the treatment of patients with breast cancer as it replaces traditional nontargeted chemotherapy with a 'smart' medication that directs the cytotoxic therapy to cancer cells by using a known biomarker.

SUBMITTER: Peddi PF 

PROVIDER: S-EPMC3860880 | biostudies-literature | 2013 Mar

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC4112743 | biostudies-literature
| S-EPMC5125250 | biostudies-literature
| S-EPMC3998859 | biostudies-literature
| S-EPMC4876844 | biostudies-literature
| S-EPMC4207068 | biostudies-literature
| S-EPMC5698565 | biostudies-literature
| S-EPMC8571323 | biostudies-literature
| S-EPMC7647719 | biostudies-literature
| S-EPMC6172075 | biostudies-literature
| S-EPMC8360077 | biostudies-literature